Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN RSV Vaccine in Healthy Adults
NCT02419391Phase 1Completed
- Sponsor
- Bavarian Nordic
- Start
- Aug 2015
- Primary completion
- Dec 2015
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MVA-BN-RSV in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Bavarian Nordic. Primary endpoints: Occurrence of serious adverse events, Occurrence of grade 3 adverse events and 3 more. Started Aug 2015; status: completed.
02
Drugs
MVA-BN-RSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02419391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419391.